We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer.
- Authors
Tanigawa, Terumi; Matoda, Maki; Yamamoto, Akiko; Nomura, Hidetaka; Okamoto, Sanshiro; Sakamoto, Kimihiko; Kondo, Eiji; Omatsu, Kohei; Kato, Kazuyoshi; Takeshima, Nobuhiro
- Abstract
<bold>Purpose: </bold>Our aim was to evaluate the efficacy and safety of S-1 in heavily pre-treated patients with advanced (FIGO stage IVB) or recurrent cervical cancer.<bold>Methods: </bold>The Institutional Review Board of our hospital approved the protocol for this retrospective phase II study. Patients with measurable disease received two oral doses of S-1 (35 mg/m(2)) daily for 4 weeks of a 6-week cycle or 2 weeks of a 3-week cycle. The antitumor effect, time to progression, overall survival, and adverse events were investigated.<bold>Results: </bold>We retrospectively analyzed relevant data of 28 patients with advanced or recurrent cervical cancer. Twenty-two patients had prior chemotherapy (not including chemoradiotherapy) and 27 had prior radiotherapy. The median number of prior chemotherapy regimens and cycles was 2 (range 0-4) and 7 (range 0-35), respectively. Two patients (7.1%) had partial response, and 10 patients (35.7%) had stable disease. Ten patients (35.7%) discontinued the therapy because of progressive disease. The response in 5 patients could not be evaluated because of termination of treatment in the middle of the first cycle. The disease control rate was 42.8%. After a median follow-up duration of 7.5 months, the median time to progression was 4.2 months (95% CI 2.7-5.4) and the median overall survival was 9.92 months (95% CI 9.20-NA). The two patients with partial response had received less prior chemotherapy.<bold>Conclusions: </bold>Oral S-1 in palliative chemotherapy is a useful and well-tolerated treatment in heavily pre-treated patients with advanced or recurrent uterine cervical cancer.
- Subjects
FLUOROPYRIMIDINES; CERVICAL cancer treatment; OVARIAN cancer; CANCER chemotherapy; RETROSPECTIVE studies; SURVIVAL analysis (Biometry); THERAPEUTICS; THERAPEUTIC use of antimetabolites; ANTIMETABOLITES; ANTINEOPLASTIC agents; CANCER relapse; COMBINATION drug therapy; CLINICAL trials; COMPARATIVE studies; FLUOROURACIL; RESEARCH methodology; HETEROCYCLIC compounds; MEDICAL cooperation; METASTASIS; RESEARCH; SURVIVAL; CERVIX uteri tumors; EVALUATION research; TREATMENT effectiveness; SALVAGE therapy; KAPLAN-Meier estimator
- Publication
Archives of Gynecology & Obstetrics, 2016, Vol 293, Issue 3, p633
- ISSN
0932-0067
- Publication type
journal article
- DOI
10.1007/s00404-015-3866-z